Collaborations and License Agreements - Additional Information (Detail) - USD ($)	1 Months Ended				3 Months Ended				9 Months Ended		12 Months Ended
	Aug. 31, 2015	Nov. 30, 2014	Mar. 31, 2014	Mar. 31, 2009	Sep. 30, 2015	Sep. 30, 2014	Jun. 30, 2011	Mar. 31, 2010	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Apr. 30, 2014
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue					$ 15,158,000	$ 873,000			$ 15,426,000	$ 18,007,000
Amounts due from pursuant to the cost-sharing provisions					2,334,000				$ 2,334,000		$ 2,341,000
Pharmstandard
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable	$ 1,500,000
Period for payment of license fees									15 days
Upfront license payment					1,000,000
Allocation of upfront payment									$ 1,000,000
Collaboration revenue					23,000				23,000
Pharmstandard | Receivable within fifteen business days of the date the license agreement is registered with the Federal Service for Intellectual Property of the Russian Federation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fees receivable					500,000				500,000
Pharmstandard | Receivable With First Marketing Authorization
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fees receivable	7,500,000
Pharmstandard | Receivable If Additional Regulatory Studies Required Prior To Approval
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fees receivable	3,000,000
Pharmstandard | Receivable For Each Additional Approval
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fees receivable	3,000,000
Clinical Efficacy Milestone | Option and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable									$ 6,000,000
Novartis
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable	15,000,000
Period for payment of license fees									15 days
Reimbursable inventory	$ 3,500,000
License and service revenue					15,000,000
Upfront license payment					15,000,000
Novartis | Sales Based Milestone Payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable									$ 150,000,000
Novartis | Clinical Efficacy Milestone
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable									53,000,000
Novartis | Regulatory Milestone Events
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable									105,000,000
Kyowa Hakko Kirin
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Expense associated with sublicensing fees payable					300,000
Ophthotech Corporation | Option and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront license payment		$ 500,000
License expiration period		2017-02
Collaborations and license agreements, payment received											$ 500,000
Collaborations and license agreements, revenue recognized					58,000				200,000
Ophthotech Corporation | Sales Based Milestone Payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, milestone payment received									45,000,000
Ophthotech Corporation | Phase Two Clinical Trials
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, milestone payment received									10,000,000
Ophthotech Corporation | Marketing Approval in the United States
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, milestone payment received									20,000,000
Ophthotech Corporation | Marketing Approval in the UK, Germany, Spain, Italy and France
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, milestone payment received									$ 20,000,000
Ophthotech Corporation | Clinical Efficacy Milestone
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, written notice period for termination									90 days
Ophthotech Corporation | Ind Submission Milestone Payment | Option and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable									$ 2,000,000
Biodesix | NSCLC POC Trial
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Responsible percentage of development and regulatory costs after cap reached												50.00%
Royalty rate to net sales of ficlatuzumab												10.00%
Amounts due from pursuant to the cost-sharing provisions					1,800,000				1,800,000
Cash received related to cost reimbursements									2,700,000
Biodesix | NSCLC POC Trial | Research and development
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments received and recorded as an increased (decreased) to expense pursuant to cost-sharing provisions					800,000	600,000			$ 2,700,000	900,000
Biodesix | NSCLC POC Trial | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Funding												$ 15,000,000
St. Vincent’s Hospital Sydney Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amendment agreement date									2015-08
Upfront license payment					1,500,000
License fees payable					18,900,000				$ 18,900,000
Biogen Idec International GmbH
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, revenue recognized			$ 14,100,000
Collaborations and license agreements, deferred revenue			14,700,000
Collaborations and license agreements, relative selling price of the deliverable			$ 600,000
Biogen Idec International GmbH | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalty payments									50,000,000
Biogen Idec International GmbH | Option and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, milestone payment received							$ 10,000,000	$ 10,000,000
Collaborations and license agreements, payment received				$ 20,000,000
Collaborations and license agreements, revenue recognized					100,000	100,000			200,000	14,400,000
Amortization of deferred revenue									10,000,000
Astellas Pharma Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amounts due from pursuant to the cost-sharing provisions					500,000	900,000			500,000	900,000
Astellas Pharma Inc. | Research and development
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments received and recorded as an increased (decreased) to expense pursuant to cost-sharing provisions					500,000	900,000			700,000	3,000,000
Astellas Pharma Inc. | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Cash received related to cost reimbursements					$ 400,000	$ 1,000,000			$ 1,000,000	$ 3,200,000